Evidence map›Paper›PMID 32508050›Full record

ArticleClinical and translational medicine2020

Novel blood-based tumor mutation algorithm and nomogram predict survival of immune checkpoint inhibitor in non-small-cell lung cancer: Results from two multicenter, randomized clinical trials.

Yunfang Yu, Yongjian Chen, Anlin Li, Qiyun Ou, Qingjian Li, Yang Gu, Dagui Lin, Wenda Zhang, Jingshu Wang, Xudong Tang and 3 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yunfang YuGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Medical Oncology, Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Yongjian ChenDepartment of Medical Oncology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Anlin LiGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Medical Oncology, Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Qiyun OuGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Medical Oncology, Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Qingjian LiGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Medical Oncology, Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Yang GuGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Medical Oncology, Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Dagui LinState key laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Wenda ZhangGuangdong Medical University, Zhanjiang, Guangdong, China.
Jingshu WangGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Medical Oncology, Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Xudong TangGuangdong Medical University, Zhanjiang, Guangdong, China.
Zhihua LiGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Medical Oncology, Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Hai HuGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Medical Oncology, Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Herui YaoGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Medical Oncology, Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.ORCID https://orcid.org/0000-0001-5520-6469

Funding

Guangdong Medical University College Students' Innovation Experiment ProjectGuangdong Science and Technology Department 2017B030314026Guangzhou Science and Technology Major ProgramMedical artificial intelligence project of Sun Yat-Sen Memorial HospitalNational Natural Science Foundation of China 81572596National Natural Science Foundation of China 81972471National Natural Science Foundation of China U1601223National Science and Technology Major ProjectNational Students' Innovation and Entrepreneurship training programNatural Science Foundation of Guangdong Province 2017A030313828Special Funds for the Cultivation of Guangdong College Students' Scientific and Technological Innovation
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID32508050
PMCPMC7403831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.